The enforcement of a much more stringent pricing revision policy, both for new products as well as off-patent brands, is behind the decline of the products currently in the market, which are forecast to drop by around 2% annually, up to 2022.
The prices of Gilead’s HCV blockbusters Sovaldi and Harvoni have been subject to significant price scrutiny and most recently the Japanese government has forced a price reduction of 50% on Opdivo, BMS’ novel PD-1/PD-L1 agent.
However, the sales decline of marketed products is counterbalanced by the optimism surrounding new therapies coming to market expected to account for 34% of sales in 2022, among the top ranking are Dupixent (Sanofi), Ibrance (Pfizer), Entresto (Novartis), Aducanumab (Biogen), and Emicizumab (Chugai).
Evaluate recently launched consensus drug forecasts for the Japanese market revealing new insights on the future outlook of the country’s Pharma & Biotech sector for benchmarking and market analysis.
References
- Evaluate Japan Drug Forecasts to 2022, © Evaluate, www.evaluategroup.com/public/Japan-Drug-Forecasts.aspx
